UCB’s Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights
UCB's Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights High-burden patient segments are driving opportunity for novel pipeline agents, while JAK inhibitors led by AbbVie's Rinvoq continue to generate strong future interest GlobeNewswire December 17, 2025 EXTON, PA, Dec. 17, 2025 (GLOBE NEWSWIRE) […]